Health-Related Quality Of Life Of Patients With Rheumatoid Arthritis Achieving Das28 Remission, Improvement In Physical Function And No Radiographic Progression After Treatment With Intravenous Golimumab

Objectives To evaluate “comprehensive remission” in patients with rheumatoid arthritis (RA) treated with intravenously administered golimumab (GLM) and the association with normalized health related quality of life (HRQOL). Methods GO-FURTHER was a multicenter, randomized, placebo-controlled study. Adult patients with active RA despite MTX therapy (≥6 tender and swollen joints, CRP ≥1.0 mg/dL, and RF and/or anti-CCP positive) were randomized to placebo (PBO) + MTX or GLM (2mg/kg) plus MTX at week 0, 2, and every 8 week thereafter (GLM group). Patients in PBO group with Results Compared to PBO+MTX group at week 24, greater proportion of patients in GLM IV group achieved DAS28 Conclusions By taking into consideration of outcomes reported by clinician and patient, and radiographic progression, “comprehensive remission” might be a more desirable treatment goal for patients with RA. Disclosure of Interest R. Westhovens Grant/research support: Janssen R & D, LLC, M. Weinblatt Grant/research support: Janssen R & D, LLC, C. Han Employee of: Janssen Pharmaceutical Services, LLC, L. Kim Employee of: Janssen R & D, LLC, M. Mack Employee of: Janssen R & D, LLC, J. Lu Employee of: Janssen R & D, LLC, D. Baker Employee of: Janssen R & D, LLC, A. Mendelsohn Employee of: Janssen R & D, LLC, C. Bingham III Grant/research support: Janssen R & D, LLC, Consultant for: Janssen R & D, LLC DOI 10.1136/annrheumdis-2014-eular.3819